secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2026-05-22T20:50:14+00:00
Accession:  0001933414-26-000090
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Therapeutics 2026 annual meeting results: directors elected, auditor ratified
--------------------------------------------------------------------------------

- Elected three Class III directors to serve until 2029: Akkaraju (67.1M for), Slingsby (67.1M for), Karydas (66.6M for).
- Ratified Ernst & Young as independent auditor for fiscal year 2026 with 72.6M votes for, 9.5K against.
- Broker non-votes of 5.6M shares on director election proposals; no non-votes on auditor ratification.
- All proposals passed with requisite affirmative votes as described in the April 8, 2026 proxy statement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341426000090/0001933414-26-000090-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341426000090/mlys-20260521.htm
  HTML page:      https://secwatch.observer/filing/0001933414-26-000090

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer